Immunomodulating polymers
Methods and products for inducing IL-2 secretion, inducing IL-10 secretion, activating T cells, suppressing IgG antibody response to specific antigen, promoting allograft survival, reducing postoperative surgical adhesion formation, and protecting against abscess formation associated with surgery, trauma or diseases that predispose the host to abscess formation are provided. The methods of the invention are accomplished using an immunomodulator which is a polymer having at least two repeating charge motifs separated by at least a certain minimum distance.
1. A method for reducing postoperative surgical adhesion formation occurring at a surgical site, comprising:
administering to a subject in need of reducing postoperative surgical adhesion formation, at a site other than at the surgical site, a pharmaceutical preparation containing an effective amount of an isolated zwitterionic polymer having at least two repeating charge motifs, wherein each repeating charge motif is composed of a positively charged free amino moiety and a negative charge, wherein the positively charged free amino moieties of the at least two repeating charge motifs are separated by a distance of at least 32 Å.
2. The method of claim 1 , wherein the zwitterionic polymer induces interleukin-2 (IL-2).
3. The method of claim 1 , wherein the zwitterionic polymer induces interleukin-10 (IL-10).
4. The method of claim 1 , wherein the molecular weight of the polymer is about 1.5 kilodaltons to about 50 kilodaltons.
5. The method of claim 4 , wherein the polymer comprises a polypeptide.
6. The method of claim 1 , wherein the polymer is a polypeptide.
7. The method of claim 1 , wherein the molecular weight of the polymer is greater than about 50 kilodaltons to less than about 500 kilodaltons.
8. The method of claim 7 , wherein the polymer comprises a polysaccharide.
9. The method of claim 1 , wherein the polymer is a polysaccharide.
10. The method of claim 1 , wherein the molecular weight of the polymer is greater than or equal to about 500 kilodaltons to about 5000 kilodaltons.
11. The method of claim 1 , wherein the administering begins before the subject undergoes a surgical procedure involving the surgical site.
12. The method of claim 11 , wherein the administering begins at least one day before the subject undergoes the surgical procedure involving the surgical site.
13. The method of claim 1 , wherein the polymer is not crosslinked.
14. The method of claim 1 , wherein the polymer is at least partly crosslinked.
15. The method of claim 1 , wherein the administering at a site other than at the surgical site is systemic.
16. The method of claim 1 , wherein the administering at a site other than at the surgical site involves a route of administration selected from the group consisting of intravenous and subcutaneous.
17. The method of claim 1 , wherein the polymer has non-repeating units.
18. The method of claim 1 , wherein the effective amount is about 1–10 mg/kg body weight of the subject.
19. A method for reducing postoperative surgical adhesion formation occurring at a surgical site, comprising:
locally administering to the surgical site of a subject in need of reducing postoperative surgical adhesion formation a pharmaceutical preparation containing an effective amount of an isolated zwitterionic non-polysaccharide polymer having at least two repeating charge motifs, wherein each repeating charge motif is composed of a positively charged free amino moiety and a negative charge, wherein the positively charged free amino moieties of the at least two repeating charge motifs are separated by a distance of at least 32 Å.
20. The method of claim 19 , wherein the molecular weight of the non-polysaccharide polymer is about 1.5 kilodaltons to about 50 kilodaltons.
21. The method of claim 19 , wherein the molecular weight of the non-polysaccharide polymer is greater than about 50 kilodaltons to less than about 500 kilodaltons.
22. The method of claim 19 , wherein the molecular weight of the non-polysaccharide polymer is greater than or equal to about 500 kilodaltons to about 5000 kilodaltons.
23. The method of claim 19 , wherein the non-polysaccharide polymer comprises a polypeptide.
24. The method of claim 19 , wherein the non-polysaccharide polymer is a polypeptide.
25. The method of claim 19 , wherein the administering begins before the subject undergoes a surgical procedure involving the surgical site.
26. The method of claim 25 , wherein the administering begins at least one day before the subject undergoes the surgical procedure involving the surgical site.
27. The method of claim 19 , wherein the non-polysaccharide polymer is not crosslinked.
28. The method of claim 19 , wherein the non-polysaccharide polymer is at least partly crosslinked.
29. The method of claim 19 , wherein the non-polysaccharide polymer has non-repeating units.
30. The method of claim 19 , wherein the effective amount is about 1–10 mg/kg body weight of the subject.
31. A method for reducing postoperative surgical adhesion formation occurring at a surgical site, comprising:
locally administering to a surgical site of a subject in need of reducing postoperative surgical adhesion formation a pharmaceutical preparation containing an effective amount of an isolated zwitterionic polysaccharide polymer having at least two repeating charge motifs, wherein each repeating charge motif is composed of a positively charged free amino moiety and a negative charge, wherein the positively charged free amino moieties of the at least two repeating charge motifs are separated by a distance of at least 32 Å.
32. The method of claim 31 , wherein the molecular weight of the polysaccharide polymer is about 1.5 kilodaltons to about 50 kilodaltons.
33. The method of claim 31 , wherein the molecular weight of the polysaccharide polymer is greater than about 50 kilodaltons to less than about 500 kilodaltons.
34. The method of claim 31 , wherein the administering begins before the subject undergoes a surgical procedure involving the surgical site.
35. The method of claim 34 , wherein the administering begins at least one day before the subject undergoes the surgical procedure involving the surgical site.
36. The method of claim 31 , wherein the polysaccharide polymer is not crosslinked.
37. The method of claim 31 , wherein the polysaccharide polymer is at least partly crosslinked.
38. The method of claim 31 , wherein the polysaccharide polymer has non-repeating units.
39. The method of claim 31 , wherein the effective amount is about 1–10 mg/kg body weight of the subject.
40. A method for reducing postoperative surgical adhesion formation occurring at a surgical site, comprising:
locally administering to a surgical site of a subject a pharmaceutical preparation containing an effective amount for reducing postoperative surgical adhesion formation of an isolated Streptococcus pneumoniae type 1 capsular polysaccharide.